Characteristic | No (%) with LEL | Univariate OR (95% CI) | P value* |
Characteristics at the time of surgery | |||
Age quartiles (years) | 0.23 | ||
31.0–58.9 (n=94) | 33 (34.0) | Reference | |
58.93–64.89 (n=95) | 37 (40.0) | 1.29 (0.72 to 2.34) | |
64.90–69.96 (n=94) | 46 (48.9) | 1.86 (1.03 to 3.34) | |
69.97–90.34 (n=95) | 41 (43.2) | 1.47 (0.82 to 2.65) | |
BMI (kg/m2) | 0.35 | ||
<25.0 (n=49) | 17 (34.7) | Reference | |
25.0–29.9 (n=90) | 34 (37.8) | 1.14 (0.55 to 2.36) | |
30.0–39.9 (n=164) | 76 (46.3) | 1.63 (0.84 to 3.16) | |
40.0 or higher (n=73) | 28 (38.4) | 1.17 (0.55 to 2.49) | |
Unknown (n=2) | 2 (100.0) | – | |
Comorbidities | |||
Diabetes | 0.06 | ||
No (n=319) | 126 (39.5) | Reference | |
Yes (n=59) | 31 (52.5) | 1.70 (0.97 to 2.96) | |
CHF | 0.82 | ||
No (n=370) | 154 (41.6) | Reference | |
Yes (n=8) | 3 (37.5) | 0.84 (0.20 to 3.57) | |
Moderate/severe renal disease | 0.41 | ||
No (n=373) | 154 (41.3) | Reference | |
Yes (n=5) | 3 (60.0) | 2.13 (0.35 to 12.92) | |
Surgical details | |||
FIGO grade | 0.82 | ||
1 or 2 (n=272) | 112 (41.8) | Reference | |
3 (n=106) | 45 (42.5) | 1.05 (0.67 to 1.66) | |
FIGO stage | 0.52 | ||
I/II (n=346) | 142 (41.0) | Reference | |
III/IV (n=32) | 15 (46.9) | 1.27 (0.61 to 2.62) | |
Histology (n (%))† | 0.58 | ||
Non-endometrioid (n=60) | 23 (38.3) | Reference | |
Endometrioid (n=318) | 134 (42.1) | 1.17 (0.67 to 2.06) | |
Study cohort‡ | <0.001 | ||
LND (n=251) | 124 (49.4) | 2.78 (1.74 to 4.44) | |
SLN (n=127) | 33 (26.0) | Reference | |
Adjuvant EBRT | 0.29 | ||
No (n=345) | 139 (40.3) | Reference | |
Yes (n=18) | 10 (55.6) | 1.85 (0.71 to 4.81) | |
Unknown (n=15) | 8 (53.3) | 1.69 (0.60 to 4.78) |
*p values are presented based on fitting univariate logistic regression models.
†Endometrioid histology included endometrioid and mixed endometrioid and mucinous histology; non-endometrioid histology included serous, clear cell, carcinosarcoma, mixed serous, and mixed clear cell histology.
‡The LND cohort consisted of patients who underwent bilateral LND prior to SLN implementation at our institution or as 'backup' after SLN mapping, and the SLN cohort consisted of patients who underwent SLN biopsy with or without side specific LND.
BMI, body mass index; CHF, congestive heart failure; EBRT, external beam radiation therapy; FIGO, International Federation of Gynecology and Obstetrics; LEL, lower extremity lymphedema; LND, lymphadenectomy; SLN, sentinel lymph node.